Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature

References

• Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol. 2017;28(12):2915–2922.
   PubMed Web of Science ®Google Scholar
• Henricks LM, van Merendonk LN, Meulendijks D, et al. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. Int J Cancer. 2019;144(9):2347–2354.
   PubMed Web of Science ®Google Scholar
• Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Williston Park). 2001;15(1Suppl 2):21–26; discussion 27.
   Google Scholar
• Lunenburg C, van der Wouden CH, Nijenhuis M, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28(4):508–517.
   PubMed Web of Science ®Google Scholar
• Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215–237.
   PubMed Web of Science ®Google Scholar
• Braakhekke JP, Renier WO, Gabreels FJ, De Abreu RA, Bakkeren JA, Sengers RC. Dihydropyrimidine dehydrogenase deficiency. Neurological aspects. J Neurol Sci. 1987;78(1):71–77.
   Web of Science ®Google Scholar
• Meta-Analysis Group In C; Levy E, Piedbois P, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16(11):3537–3541.
   Web of Science ®Google Scholar
• Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki AM. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol. 2010;65(2):403–406.
   PubMed Web of Science ®Google Scholar
• Boisdron-Celle M, Capitain O, Faroux R, et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach. Semin Oncol. 2017;44(1):13–23.
   PubMed Web of Science ®Google Scholar
• Varughese LA, Lau-Min KS, Cambareri C, et al. DPYD and UGT1A1 pharmacogenetic testing in patients with gastrointestinal malignancies: an overview of the evidence and considerations for clinical implementation. Pharmacotherapy. 2020;40(11):1108.
   PubMed Web of Science ®Google Scholar
• Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–216.
   PubMed Web of Science ®Google Scholar
• Henricks LM, Lunenburg C, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459–1467.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639–1650.
   PubMed Web of Science ®Google Scholar
• Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17(10):3455–3468.
   PubMed Web of Science ®Google Scholar
• Henricks LM, Lunenburg CA, Meulendijks D, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1277–1286.
   PubMed Web of Science ®Google Scholar
• Stavraka C, Pouptsis A, Okonta L, et al. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. Breast Cancer Res Treat. 2019;175(2):511–517.
   Web of Science ®Google Scholar
• Saif MW. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genomics Proteomics. 2013;10(2):89–92.
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993;53(22):5433–5438.
   PubMed Web of Science ®Google Scholar
• Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 1991;68(3):499–501.
   PubMed Web of Science ®Google Scholar
• Fleming RA, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52(10):2899–2902.
   PubMed Web of Science ®Google Scholar
• Ackland SP, Garg MB, Dunstan RH. Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem. 1997;246(1):79–85.
   PubMed Web of Science ®Google Scholar
• Morsman JM, Sludden J, Ameyaw MM, et al. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol. 2000;50(3):269–272.
   PubMed Web of Science ®Google Scholar
• Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12(11):2248–2253.
   PubMed Web of Science ®Google Scholar
• Sohn DR, Cho MS, Chung PJ. Dihydropyrimidine dehydrogenase activity in a Korean population. Ther Drug Monit. 1999;21(2):152–154.
   Web of Science ®Google Scholar
• Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006;12(18):5491–5495.
   PubMed Web of Science ®Google Scholar
• Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol. 1995;14(1):1–6.
   PubMed Web of Science ®Google Scholar
• Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14(11):1255–1272.
   PubMed Web of Science ®Google Scholar
• Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg AB, Akkafa F. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer. Anticancer Res. 2007;27(6B):3899–3902.
   Web of Science ®Google Scholar
• He YF, Wei W, Zhang X, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J Clin Pharm Ther. 2008;33(3):307–314.
   PubMed Web of Science ®Google Scholar
• Elraiyah T, Jerde CR, Shrestha S, et al. Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clin Pharmacol Ther. 2017;101(3):382–390.
   Web of Science ®Google Scholar
• Maekawa K, Saeki M, Saito Y, et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet. 2007;52(10):804–819.
   Web of Science ®Google Scholar
• Hishinuma E, Narita Y, Saito S, et al. Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1070 Japanese individuals. Drug Metab Dispos. 2018;46(8):1083–1090.
   Web of Science ®Google Scholar
• Yokoi K, Nakajima Y, Matsuoka H, et al. Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer. Cancer Sci. 2020;111(9):3359–3366.
   Web of Science ®Google Scholar
• Slatkin M. Linkage disequilibrium–understanding the evolutionary past and mapping the medical future. Nat Rev Genet. 2008;9(6):477–485.
   PubMed Web of Science ®Google Scholar
• Zaanan A, Dumont LM, Loriot MA, Taieb J, Narjoz C. A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant. Clin Pharmacol Ther. 2014;95(2):136.
   Web of Science ®Google Scholar
• Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013;94(1):158–166.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, et al. Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: myth or reality? South Asian J Cancer. 2016;5(4):182–185.
   PubMedGoogle Scholar
• Negarandeh R, Salehifar E, Saghafi F, et al. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer. 2020;20(1):560.
   Web of Science ®Google Scholar
• Khushman M, Patel GK, Hosein PJ, et al. Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. J Gastrointest Oncol. 2018;9(3):416–424.
   PubMed Web of Science ®Google Scholar
• Maharjan AS, McMillin GA, Patel GK, et al. The prevalence of DPYD*9A(c.85T>C) genotype and the genotype-phenotype correlation in patients with gastrointestinal malignancies treated with fluoropyrimidines: updated analysis. Clin Colorectal Cancer. 2019;18(3):e280–e286.
   Web of Science ®Google Scholar
• Varma A, Jayanthi M, Dubashi B, Shewade DG, Sundaram R. Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin. Drug Metab Pers Ther. 2020;35:4.
   Google Scholar
• Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74(9):2545–2554.
   PubMed Web of Science ®Google Scholar
• Loganayagam A, Arenas Hernandez M, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013;108(12):2505–2515.
   PubMed Web of Science ®Google Scholar
• Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11(16):5886–5892.
   PubMed Web of Science ®Google Scholar
• Naushad SM, Hussain T, Alrokayan SA, Kutala VK. Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. J Gene Med. 2020;23:e3289.
   Web of Science ®Google Scholar
• Hariprakash JM, Vellarikkal SK, Keechilat P, et al. Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data. Pharmacogenomics. 2018;19(3):227–241.
   PubMed Web of Science ®Google Scholar
• Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM. Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity - What are the options? Clin Pharmacol Ther. 2020;23(1):e3289.
   Google Scholar
• Loriot MA, Ciccolini J, Thomas F, et al. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Bull Cancer. 2018;105(4):397–407. Swedish.
   PubMed Web of Science ®Google Scholar
• Martens FK, Huntjens DW, Rigter T, Bartels M, Bet PM, Cornel MC. DPD testing before treatment with fluoropyrimidines in the Amsterdam UMCs: an evaluation of current pharmacogenetic practice. Front Pharmacol. 2019;10:1609.
   PubMed Web of Science ®Google Scholar
• National Health Service E. Clinical Commissioning Urgent Policy Statement Pharmacogenomic Testing for DPYD Polymorphisms with Fluoropyrimidine Therapies [URN 1869] (200603P); 2020.
   Google Scholar
• Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443.
   PubMed Web of Science ®Google Scholar
• Coenen MJH, Paulussen ADC, Breuer M, et al. Evolution of dihydropyrimidine dehydrogenase diagnostic testing in a single center during an 8-year period of time. Curr Ther Res Clin Exp. 2019;90:1–7.
   Web of Science ®Google Scholar
• Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131–2138.
   PubMed Web of Science ®Google Scholar
• Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32(10):1031–1039.
   PubMed Web of Science ®Google Scholar
• Henricks LM, Lunenburg C, de Man FM, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2019;107:60–67.
   PubMed Web of Science ®Google Scholar
• Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227–234.
   PubMed Web of Science ®Google Scholar
• Lee B, Lingaratnam S, Alexander M, et al. Feasibility of Implementation of a pharmacist-Led DPYD gene testing for patients newly commencing 5-Fluorouracil or Capecitabine. Asia Pac J Clin Oncol. 2020;16(S8):108–207.
   Google Scholar
• Elsum I, McEwan C, Kowal EE, Cadet-James Y, Kelaher M, Woodward L.Inclusion of Indigenous Australians in biobanks: a step to reducing inequity in health care. Med J Aust. 2019;211(1):7–9.
   Web of Science ®Google Scholar
• Kowal EE. Genetic research in Indigenous health: significant progress, substantial challenges. Comment. Med J Aust. 2012;197(7):384.
   Web of Science ®Google Scholar
• Mercier C, Brunet C, Yang C, et al. Pharmacoeconomic study in head and neck cancer patients: impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs. J Clin Oncol. 2009;27(15_suppl):6515.
   Web of Science ®Google Scholar
• Launay M, Dahan L, Duval M, et al. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol. 2016;81(1):124–130.
   PubMed Web of Science ®Google Scholar
• Zhao C, Li S, Liu Q. Meta-analysis of molecular targeted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter? J Chemother. 2016;28(4):321–327.
   PubMed Web of Science ®Google Scholar
• Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiader CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136(3):730–739.
   PubMed Web of Science ®Google Scholar
• Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013;73(6):1958–1968.
   PubMed Web of Science ®Google Scholar
• Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin Proc. 2014;89(1):131–136.
   PubMed Web of Science ®Google Scholar